nanoMR has raised $13 million in venture capital funding. The biotechnology company’s series B fundraising was led by Excel Venture Management, while Healthcare Ventures also joined in.
Existing partner’s vSpring Capital, Dow Chemical Company and Sun Mountain Capital also participated in the deal. nanoMR aims to use the proceeds to develop commercial instruments for the clinical microbiology market, perform clinical studies and prepare for product launch.
Click here for the release from nanoMR.